ReviewNature reviews. Clinical oncology2012
Overcoming implementation challenges of personalized cancer therapy.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 146 citations in OpenAlex.
- Development and Pre-clinical Feasibility of a Catheter-Based Platform for Interventional Phase-0 Drug Response Measurements.Annals of biomedical engineering · 2026Article
- An Interventional Radiology Method for In Situ Assessments of Cancer Drug Response: Preclinical Development, Feasibility, and Safety.Radiology. Imaging cancer · 2025Article
- Precise Electromagnetic Modulation of the Cell Cycle and Its Applications in Cancer Therapy.International journal of molecular sciences · 2025Review
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.BMC cancer · 2025Article
- Editorial: design considerations for future personalized vaccination approaches.Nanomedicine (London, England) · 2025Article
- Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.Journal of the National Cancer Center · 2024Article
- Computational Approaches: A New Frontier in Cancer Research.Combinatorial chemistry & high throughput screening · 2024Review
- A nationwide survey of the current status of radiation oncology teaching in Spanish medical schools.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Article
- The EDN1/EDNRA/β‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation.International journal of oncology · 2023Article
- Clinical prospects of WRN inhibition as a treatment for MSI tumours.NPJ precision oncology · 2022Review
- Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis.Cancer informatics · 2022Article
- The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients.IEEE transactions on bio-medical engineering · 2022Article
- Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.International journal of nanomedicine · 2022Review
- Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients.Diagnostics (Basel, Switzerland) · 2021Article
- Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy.Drug delivery and translational research · 2021Review
- Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.Cancers · 2021Review
- Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.International journal of molecular sciences · 2021Review
- Non-genetic mechanisms of therapeutic resistance in cancer.Nature reviews. Cancer · 2020Review
- Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey.JCO oncology practice · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.